<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-049906</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Stability of NT-ProBNP in patients with systolic heart failure</dc:title>
<dc:description xml:lang="en">Natriuretic peptides are extremely useful in the diagnosis and prognosis of patients with heart failure. However, it is not clear whether their values are stable. We carried out a prospective study of 30 consecutive ambulatory patients (mean age, 62.6 [12.2] years) with stable systolic heart failure, as determined by the 6-minute walk test, who were in New York Heart Association class II or III and who had a left ventricular ejection fraction &lt;30% (mean ejection fraction, 24.2% [6.68%]). At baseline, the mean N-terminal pro-brain natriuretic peptide (NT-proBNP) level and the mean distance walked in 6 minutes were 2237.3 pg/mL and 348.26 m, respectively. At 3-month follow-up, the corresponding values were 2096.2 pg/mL and 372.05 m, respectively. No significant difference was observed in NT-proBNP level or in distance walked in 6 minutes between baseline and 3 months (P=.8). Overall, there was a good correlation (r=0.94; P&lt;.001) between the plasma NT-proBNP level at baseline and at 3 months in patients with stable chronic heart failure due to systolic dysfunction in New York Heart Association class II or III</dc:description>
<dc:creator>Teresa-Galván, Eduardo de</dc:creator>
<dc:creator>Domínguez-Franco, Antonio</dc:creator>
<dc:creator>Morell, Miguel</dc:creator>
<dc:creator>Gómez-Doblas, Juan J</dc:creator>
<dc:creator>Fernández-Moyano, María A</dc:creator>
<dc:creator>Jiménez-Navarro, Manuel F</dc:creator>
<dc:creator>Gómez-Hernández, Gemma</dc:creator>
<dc:creator>Molero, Encarnación</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los péptidos natriuréticos tienen un alto valor diagnóstico y pronóstico en pacientes con insuficiencia cardiaca, pero desconocemos la estabilidad de sus valores. Determinamos en 2 visitas ambulatorias los valores de N terminal pro-BNP (NT-proBNP) de 30 pacientes consecutivos con insuficiencia cardiaca estable [New York Heart Association (NYHA) II-III] (test 6 min) por disfunción sistólica [función ventricular izquierda deprimida (FEVI) &lt; 30%] separadas entre sí 3 meses. Tenían una edad media de 62,6 ± 12,2 años y una fracción de eyección del 24,2 ± 6,68%. No encontramos diferencias significativas entre los valores basales del NT-proBNP como test de los 6 min (2.237,3 pg/ml y 348,26 m) y a los 3 meses (2.096,2 pg/ml y 372,05 m). El coeficiente de correlación intraclase entre los valores basales y a los 3 meses de NT-proBNP fue de 0,94 (p &lt; 0,001). Existe una buena correlación entre los valores basales y a los 3 meses de las concentraciones plasmáticas de NT-proBNP en pacientes con insuficiencia cardiaca crónica estable (NYHA II-III) por disfunción sistólica</dc:description>
<dc:source>Rev Esp Cardiol;59(10): 1075-1078, oct. 2006. tab, graf</dc:source>
<dc:identifier>ibc-049906</dc:identifier>
<dc:title xml:lang="es">Estabilidad de NT-proBNP en pacientes con insuficiencia cardiaca sistólica</dc:title>
<dc:subject>^d23568^s22062</dc:subject>
<dc:subject>^d33842^s22062</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d2347^s22062</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d28563</dc:subject>
<dc:type>article</dc:type>
<dc:date>200610</dc:date>
</metadata>
</record>
</ibecs-document>
